Q-linea AB (publ) (QLINEA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome everyone to our presentation of our Q1 report. I know that we're going into a long weekend here in Sweden, so I really appreciate everyone taking the time to join. I'll start off with the usual disclaimer here. We'll take this as read and understood. So we'll go through the fairly regular agenda we've done on these. I'll give you some of the commercial updates here. I'll speak to our recent FDA clearance and what that means for us in the market and for our customers. And then I'll spend a little bit of time on our priorities for the remainder of the year before handing over to Krister to go through the financials and obviously the Q&A at the end. So with that, and for those who don't have very much time with us today, some highlight messages I would want you to take away from this presentation. The first point is that Q1 of this year was thus far a record one for moving instruments into the market. We put seven instruments out there. I'll talk more to that. We also saw our highest demand yet for consumables. This is notwithstanding an approval that came during April for the FDA clearance. So this is our big news for this month. It materially expands our value proposition for U.S. customers. I'll speak to that. We think this will make a very real difference in the market overall. over the coming months and quarters. And with that, we do expect to see the U.S. kind of jumpstart from approval here. I'll speak to the pipeline we're working with and the dynamics there. Then we have a little bit of an update on our R&D side. We expect to be able to launch our dedicated isolate kit during Q3 of this year under research use only registration. I'll speak to the background of this one and what the opportunity is, but we're very excited for that news coming to...